NASDAQ | VICL: 1.25  +0.00
products
Products

Independent Programs

Corporate Collaborations

By United States Department of Agriculture
Research indicates exploration and/or evaluation of a potential product candidate in a nonclinical laboratory setting.
Preclinical indicates that a specific product candidate in a nonclinical setting has shown functional activity that is relevant to a targeted medical need, and is undergoing toxicology testing in preparation for filing an Investigational New Drug (IND) application.
Phase 1 clinical trials are typically conducted with a small number of patients or healthy subjects to evaluate safety, determine a safe dosage range, identify side effects, and, if possible, gain early evidence of effectiveness.
Phase 2 clinical trials are conducted with a larger group of patients to evaluate effectiveness of an investigational drug for a defined patient population, and to determine common short-term side effects and risks associated with the drug.
Phase 3 clinical trials involve large scale, multi-center, comparative trials that are conducted with patients afflicted with a target disease to evaluate the overall benefit-risk relationship of the investigational drug and to provide an adequate basis for product labeling.

Intended Use:
First-line treatment for metastatic melanoma

Technology: DNA + DMRIE-DOPE

Collaborator: AnGes

Intended Use:
Prevent CMV viral reactivation/infection and disease after transplant

Technology: DNA + Poloxamer

Collaborator: Astellas

Intended Use:
Prevent infection before and during pregnancy to preclude fetal transmission

Technology: DNA Vaxfectin®

Intended Use:
Prevent recurring flare-ups, reduce viral shedding and transmission

Technology: DNA + Vaxfectin®

Collaborator: Univ of Washington, Univ of Texas

Intended Use:
Induce local growth of blood vessels to restore blood flow to limbs affected by ischemia

Technology: DNA

Collaborator: AnGes
AnGes successfully completed a small Phase 3 trial in Japan and is currently preparing for a large multinational Phase 3 trial intended to support filings for marketing approval in the United States, Europe and Japan.

Intended Use:
Protect farm-raised salmon from infection and disease when exposed to infected wild salmon

Technology: DNA

Collaborator: Aqua Health (Novartis)

Intended Use:
Adjunct treatment to increase survival time of dogs with oral melanoma

Technology: DNA

Collaborator: Merial

Intended Use:
Prevent and/or treat infection, disease, and/or viral shedding

Technology: DNA + Vaxfectin®

Collaborator: NMRC

Government Collaborations

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.